Ketorolac Trometamol Rompharm (Ketorolac Trometamol)

Ketorolac Trometamol works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the synthesis of prostaglandins. Reduced prostaglandin levels diminish inflammation and nociceptor sensitisation, leading to effective pain relief and anti‑inflammatory effects.

The specific dose and duration of Ketorolac Trometamol Rompharm are determined by the prescribing clinician based on the patient’s condition, weight, renal function and other clinical factors. Healthcare professionals follow local guidelines and product labeling to set an appropriate regimen.

Safety of Ketorolac Trometamol during pregnancy and lactation has not been established. Because of potential risks to the fetus and newborn, it is generally avoided in pregnant or nursing women unless the benefits clearly outweigh the risks and a qualified healthcare provider approves its use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Ketorolac Trometamol offers potent non‑opioid analgesia comparable to stronger NSAIDs but with a faster onset than many oral formulations. Unlike opioids, it does not cause respiratory depression, but it shares typical NSAID risks such as gastrointestinal bleeding and renal effects. It is often chosen when a short‑acting, injectable analgesic is required.

The product should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from direct light, moisture and extreme temperature fluctuations. Do not freeze the solution, and keep the vial sealed until ready for use to maintain sterility.

Ketorolac Trometamol Rompharm is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional, who selects the appropriate route, dose volume and injection site according to the patient’s clinical needs and prescribing information.

The most serious risks include gastrointestinal bleeding or ulceration, acute renal impairment, severe hypersensitivity reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored for signs of bleeding, kidney dysfunction and allergic reactions, especially during prolonged or high‑dose therapy.

Ketorolac Trometamol Rompharm is contraindicated in patients with severe renal impairment, active peptic ulcer disease, known hypersensitivity to ketorolac or other NSAIDs, uncontrolled hypertension, and those with a history of serious cardiovascular events. It should also be avoided in patients receiving concurrent anticoagulant therapy unless closely monitored.